More on COGT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $31.21 |
|
|||
| Open | $31.21 | ||||
| 52 Wk High | $5.57 | ||||
| 52 Wk Low | $2.90 | ||||
| Day High | $31.21 | ||||
| Day Low | $31.21 | ||||
| P/E | 141.86 | ||||
| EPS | $0.22 | ||||
| Volume | 1 | ||||
- Form 4 Cogent Biosciences, Inc. For: Oct 01 Filed by: Ferrante Karen Jean
- H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
- FDA accepts Cogent Biosciences NDA for bezuclastinib in AdvSM
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
- Form 144 Cogent Biosciences, Inc. Filed by: Morris Arlene
- H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
- Cogent (COGT) PT Raised to $55 at Piper Sandler
- Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Flynn James E
- Cogent (COGT) PT Raised to $52 at Guggenheim
- Form 8-K Cogent Biosciences, Inc. For: Aug 10
Entities mentioned with COGT
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- S3 | View Related Stories »
- Show More...
